261
Participants
Start Date
July 31, 2011
Primary Completion Date
October 31, 2011
Study Completion Date
October 31, 2011
PP4001
50 mg, 1 dose every 12 hours x 4 doses
PP4001
100 mg, 1 dose every 12 hours x 4 doses
PP4001
200 mg, 1 dose every 12 hours x 4 doses
Placebo
Placebo, 1 dose every 12 hours x 4 doses
AccuMed Research Associates, Garden City
Hawthorne Medical Research, Inc., Winston-Salem
Wake Research Associates, Raleigh
Ellipsis Research Group, LLC, Columbia
Palmetto Clinical Research, LLC, Greenville
Soapstone Center for Clinical Research, Decatur
Health Awareness, Inc., Jupiter
Tampa Bay Medical Research, Clearwater
Urology Center of Central Florida/Triquest Clinical Research Inc., Saint Cloud
Drug Research and Analysis Corp., Montgomery
InvestiClin Research, Brentwood
Hometown Urgent Care and Research, Groveport
Hometown Urgent Care and Research, Springfield
Hutzel Women's Health Research, Detroit
Bellevue Family Practice/Clinical Research Advantage, Bellevue
R/D Clinical Research, Inc., Lake Jackson
Clinical Trials of Texas, San Antonio
Advanced Research Associates, Corpus Christi
Central Phoenix Medical Clinic/Clinical Research Advantage, Phoenix
Mesa Family Medical Center/Clincal Research Advantage, Mesa
Desert Clinical Research/Clinical Research Advantage, Mesa
Clinical Research Center of Nevada, Las Vegas
Medical Center for Clinical Research, San Diego
Women's Health Care Research, San Diego
Northern California Research, Sacramento
Lead Sponsor
Pinnacle Pharmaceuticals, Inc.
INDUSTRY